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Abstract: Bicuspid aortic valve (BAV), the most common congenital heart defect, is associated with an
increased prevalence of aortic dilation, aortic rupture and aortic valve calcification. Endothelial cells
(ECs) play a major role in vessel wall integrity. Little is known regarding EC function in BAV patients
due to lack of patient derived primary ECs. Endothelial colony forming cells (ECFCs) have been
reported to be a valid surrogate model for several cardiovascular pathologies, thereby facilitating an
in vitro system to assess patient-specific endothelial dysfunction. Therefore, the aim of this study was
to investigate cellular functions in ECFCs isolated from BAV patients. Outgrowth and proliferation
of ECFCs from patients with BAV (n = 34) and controls with a tricuspid aortic valve (TAV, n = 10)
were determined and related to patient characteristics. Interestingly, we were only able to generate
ECFCs from TAV and BAV patients without aortic dilation, and failed to isolate ECFC colonies from
patients with a dilated aorta. Analyzing EC function showed that while proliferation, cell size and
endothelial-to-mesenchymal transition were similar in TAV and BAV ECFCs, migration and the
wound healing capacity of BAV ECFCs is significantly higher compared to TAV ECFCs. Furthermore,
calcification is blunted in BAV compared to TAV ECFCs. Our results reveal ECs dysfunction in BAV
patients and future research is required to unravel the underlying mechanisms and to further validate
ECFCs as a patient-specific in vitro model for BAV.
Keywords: endothelial colony forming cell; ECFC; blood outgrowth endothelial cell; BOEC; bicuspid
aortic valve; BAV; aortic dilation; calcification; migration
1. Introduction
Bicuspid aortic valve (BAV) is the most common congenital heart defect, present in 1–2% of the
adult population worldwide. While a normal aortic valve consists of three leaflets (tricuspid aortic
valve, TAV), a BAV has only two free moveable/floating leaflets either with or without a raphe. BAV
can occur sporadically or can be inherited, and mutations in e.g., NOTCH1, TGFBR1 and SMAD6, have
been reported to be associated with BAV [1,2]. Furthermore, there is a remarkable male preponderance
of 3:1 in the total population. Patients with a BAV have an increased prevalence of dilation and even
rupture of the ascending aorta, while aortic valve regurgitation or stenosis can also occur [3].
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Aortic dilation can become a life-threatening situation manifested by destructive changes in
the aortic architecture, caused, among other reasons, by dedifferentiation of contractile smooth
muscle cells (SMCs) and elastic lamella fragmentation [4]. To understand the cellular and molecular
mechanisms driving the pathogenesis in aortic dilation, research over recent decades has mainly
focused on SMCs and the role of biochemical signals to steer their differentiation and extracellular
matrix modulation within the media of the aorta [5]. Little is known about a possible role of the
endothelium in aortic dilation in BAV patients. Recently, the endothelial cells (ECs) have become of
increased interest in BAV pathology (reviewed in [6]). Interestingly, altered EC migration, EC function
and endothelial-to-mesenchymal transition (EndoMT) have been described in BAV patients [7,8].
Furthermore, mutations in ROBO4 have recently been identified in BAV patients, which was shown to
impair the barrier function of the ECs and induce EndoMT [9].
It is extremely difficult to obtain primary ECs from ascending aorta to study endothelial function,
especially when matched controls are needed for comparison. Furthermore, patient-derived aortic ECs
are a heterogeneous, non-proliferative population of ECs, derived from end-stage disease material [10].
Therefore, circulating endothelial progenitor cells have become an important tool to study EC function
in different cardiovascular diseases.
There are 2 main types of circulating endothelial progenitor cells described; namely, endothelial
progenitor cells (EPCs) and endothelial colony forming cells (ECFCs). While EPCs express some
EC markers such as PECAM1, von Willebrand Factor and VE-cadherin, it is now well established
that these cells are CD14+ circulating mononuclear cells, instead of true endothelial progenitors [11].
Previous studies have shown that the number of EPCs is reduced in BAV patients with or without
aneurysms, when compared to TAV patients with or without aneurysms, respectively [12]. In addition,
BAV patients with dysfunctional valves have reduced numbers of circulating EPCs when compared to
BAV patients with a normal functioning valve [13]. Moreover, EPCs exhibit a decreased migratory
capacity in BAV patients with dysfunctional valves [13]. ECFCs, also known as blood outgrowth
endothelial cells (BOECs), are the real circulating endothelial progenitor cells. ECFCs can be isolated
from amongst other peripheral blood and give rise to a cell population indistinguishable from mature
ECs [11,14]. These cells are able to contribute to vessel formation in vivo and have a high proliferative
potential [11,15]. ECFCs have been used as a proxy to study EC function in diseases such as pulmonary
arterial hypertension (PAH), diabetes and ischemic heart disease [16–19]. For example, in PAH, it is
reported that failure of ECFC outgrowth is associated with clinical worsening [20].
To date, there is no data available describing the function of ECFCs in BAV patients. Given the
important role of EC function in vessel stability, in this study we aimed to investigate EC function in
BAV patients. Because ECFCs resemble EC function very well and isolating ECs from aortic tissue is
not feasible, studying these cells may provide a valuable insight into EC functioning in BAV patients.
Therefore, we isolated ECFCs from BAV patients and participants with a TAV serving as healthy
controls. The outgrowth and proliferation of ECFCs was quantified and related to patient characteristics.
Moreover, migration and response to calcifying stimulation was assessed in the ECFCs. Our results
demonstrate ECFC dysfunction in BAV patients compared to healthy TAV controls. We expect that
this will encourage other researchers to further develop and characterize ECFCs as an in vitro model
for BAV.
2. Results
2.1. No Successful Growth of ECFC Colonies Isolated from Patients with a Dilated Aorta
We first investigated whether ECFCs can be isolated from BAV patients and TAV controls.
To isolate ECFC colonies, peripheral blood derived mononuclear cells were collected from patients
(n = 34) and healthy participants (controls, n = 10). There were no significant differences between the
included control participants and the patients with regard to age, height, weight and gender (Table 1).
The isolated mononuclear cells fractions were seeded, and wells were monitored for colonies to appear
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after 2–5 weeks. In total, 74 colonies appeared, but not all colonies resulted in a successful ECFC
patient-derived cell line. Growth of an ECFC colony was considered successful if they were able to
proliferate for at least 8 passages. Unsuccessful ECFC isolations were those colonies that showed a
decrease in proliferation rate, and adopted morphologically a senescent, mesenchymal phenotype
(Figure 1A).
Table 1. Participant characteristics.
TAV (10) BAV (34)
Male Sex, n (%) 5 (50) 18 (52.9)
Age, Year (stdev) 32.0 (10.5) 38.4 (15.5)
Height, cm (stdev) 179.4 (15.8) 176 (11.0)
Weight, kg (stdev) 74.8 (11.2) 76.9 (14.5)
Valve Types, n (%) 1
Type 0 - 5 (14.7)
Type 1 L-R - 17 (50)
Type 1 R-N - 4 (11.8)
Type 2 L-R, R-N - 2 (5.9)
Unknown - 6 (17.6)
Dilation, Yes (%) 0 (0) 17 (50) *
Aortic Size, mm (stdev) all non-dilated dilated
Aorta ascendens 28.6 (3.0) 30.2 (3.0) 43.1 (5.5)
Stenosis, n (%)
Severe 0 (0) 4 (11.8)
Moderate 0 (0) 6 (17.6)
Mild 0 (0) 15 (14.7)
None 10 (100) 19 (55.9)
Insufficiency, n (%)
Moderate 0 (0) 10 (29.4)
Mild 0 (0) 12 (35.3)
None 10 (100) 17 (50)
1 Valve classification according to Sievers [21].
There was no correlation between successful and unsuccessful ECFC isolations when comparing
gender, age, length and weight between TAV control and BAV patients (Table 2). From the TAV control
participants, 30% of the isolations lead to successful colony growth. For the isolations of BAV patients
derived ECFCs there was a trend towards decrease in isolation efficiency with a success rate of 14.7%
(χ2(1) = 1.22, p = 0.27). Interestingly, all isolations from BAV patients that did result in an ECFC cell
line were isolated from BAV patients without aortic dilation (non-dilated BAV: nBAV, n = 17). We were
unable to isolate stable ECFCs from BAV patients with aortic dilation (dilated BAV: dBAV, n = 17).
The decreased isolation efficiency observed in dBAV patients was significantly different compared to
both TAV control samples and nBAV patients (χ2(2)= 6.16, p = 0.046) (Figure 1B). When comparing
patient characteristics, dBAV patients did have a significantly higher age and bodyweight (Table A1).
Interestingly, the observed decrease in successful ECFC isolations was not due to a decrease in total
number of colonies that appeared after seeding of the mononuclear cells (Figure 1B) or the number of
colonies observed per patient (Figure 1C). There was a significant decrease in success per colony after
the first passage in colonies from dBAV patients compared to colonies from TAV patients (χ2(1)= 7.075,
p = 0.008) (Figure 1D). Our results demonstrate for the first time that the establishment of stable ECFCs
cultures from BAV patients with an aortic dilation is compromised.
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Figure 1. Successful growth of ECFCs in TAV and BAV non-dilated patients. (A) Representative 
images of a successful (left) and an unsuccessful (right) ECFC colony. Scalebar is 200 μm. (B) Graph 
showing the percentage of patient isolations resulting in a colony and the percentage of patient 
isolations resulting in a cell line. (C) Graph indicating the average number of colonies per isolation. 
(D) Graph showing the percentage of colonies resulting in a successful ECFC cell line. * p < 0.05, ** p 
< 0.01. 
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 TAV (3, 30.0%) BAV (5, 14.7%) 
Male Sex, n (%) 2 (66.7)  3 (60) 
Age, Year (stdev) 34.0 (12.2) 25.8 (5.9) 
Height, cm (stdev) 186.3 (5.1) 174.6 (14.0) 
Weight, kg (stdev) 77.7 (10.0) 66.4 (10.3) 
Valve Types, n (%)     
Type 0 - 2 (20) 
Type 1 L-R - 2 (20) 
Type 1 R-N - 0 (0) 
Type 2 L-R, R-N - 0 (0) 
Unknown - 1 (20) 
Dilation, Yes (%) 0 (0) 0 (0)* 
Aorta Ascendens Size, mm (stdev) 28 (2.0) 29.8 (2.3) 
Stenosis, n (%)      
Severe 0 (0) 0 (0) 
Moderate 0 (0) 1 (20) 
Mild 0 (0) 1 (20) 
None 3 (100) 3 (60) 
Insufficiency, n (%)       
Moderate 0 (0) 1 (20) 
Mild 0 (0) 1 (20) 
None 3 (100) 3 (60) 
There was no correlation between successful and unsuccessful ECFC isolations when comparing 
gender, age, length and weight between TAV control and BAV patients (Table 2). From the TAV 
control participants, 30% of the isolations lead to successful colony growth. For the isolations of BAV 
Figure 1. Successful growth of ECFCs in TAV and BAV non-dilated patients. (A) Representative images
of a successful (left) and an unsuccessful (right) ECFC colony. Scalebar is 200 µm. (B) Graph showing
the percentage of patient isolations resulting in a colony and the percentage of patient isolations
resulting in a cell line. (C) Graph indicating the average number of colonies per isolation. (D) Graph
showing the percentage of colonies resulting in a successful ECFC cell line. * p < 0.05, ** p < 0.01.
Table 2. Participant characteristics successful ECFC isolations.
TAV (3, 30.0%) BAV (5, 14.7%)
Male Sex, n (%) 2 (66.7) 3 (60)
Age, Year (stdev) 34.0 (12.2) 25.8 (5.9)
Height, cm (stdev) 186.3 (5.1) 174.6 (14.0)
Weight, kg (stdev) 77.7 (10.0) 66.4 (10.3)
Valve Types, n (%)
Type 0 - 2 (20)
Type 1 L-R - 2 (20)
Type 1 R-N - 0 (0)
Type 2 L-R, R-N - 0 (0)
Unknown - 1 (20)
Dilation, Yes (%) 0 (0) 0 (0) *
Aorta Ascendens Size, mm (stdev) 28 (2.0) 29.8 (2.3)
Stenosis, n (%)
Severe 0 (0) 0 (0)
Moderate 0 (0) 1 (20)
Mild 0 (0) 1 (20)
None 3 (100) 3 (60)
Insufficiency, n (%)
Moderate 0 (0) 1 (20)
Mild 0 (0) 1 (20)
None 3 (100) 3 (60)
Ther was no correlation between successful and unsuccessful ECFC isolations when comparing
gender, age, length and weight be ween TAV control and BAV patients (Table 2). From the TAV control
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participants, 30% of the isolations lead to successful colony growth. For the isolations of BAV patients
derived ECFCs there was a trend towards decrease in isolation efficiency with a success rate of 14.7%
(χ2(1) = 1.22, p = 0.27). Interestingly, all isolations from BAV patients that did result in an ECFC cell
line were isolated from BAV patients without aortic dilation (non-dilated BAV: nBAV, n = 17). We were
unable to isolate stable ECFCs from BAV patients with aortic dilation (dilated BAV: dBAV, n = 17).
The decreased isolation efficiency observed in dBAV patients was significantly different compared to
both TAV control samples and nBAV patients (χ2(2) = 6.16, p = 0.046) (Figure 1B). When comparing
patient characteristics, dBAV patients did have a significantly higher age and bodyweight (Table A1).
Interestingly, the observed decrease in successful ECFC isolations was not due to a decrease in total
number of colonies that appeared after seeding of the mononuclear cells (Figure 1B) or the number of
colonies observed per patient (Figure 1C). There was a significant decrease in success per colony after
the first passage in colonies from dBAV patients compared to colonies from TAV patients (χ2(1) = 7.075,
p = 0.008) (Figure 1D). Our results demonstrate for the first time that the establishment of stable ECFCs
cultures from BAV patients with an aortic dilation is compromised.
2.2. EndoMT Response is Similar in TAV and BAV ECFCs
Recent studies demonstrate that EndoMT is altered in BAV patients compared to TAV
controls [7,9,22,23]. To investigate this, we examined the ability of ECFCs to undergo EndoMT
in response to TGFβ stimulation. After 48 h of TGFβ stimulation, we determined the expression levels
of the EndoMT associated genes SNAI1 (encoding Snail), TAGLN (encoding SM22a) and FN1 (encoding
Fibronectin) by qRT-PCR. As expected, an increase in mRNA expression of these EndoMT target genes
was observed in both TAV and BAV ECFCs upon TGFβ stimulation. There was no difference TGFβ
induced EndoMT between the TAV and BAV ECFCs (Figure A1).
2.3. Proliferation and Cell Size Are Similar in TAV and BAV ECFCs
During cell culture, we observed an apparent variation in cell size and proliferation between the
different ECFC cell lines (Figure 2A). These differences were not depending on confluence of the wells
since they were observed in both confluent and non-confluent situations. Next, cell surface area was
determined to investigate a potential relationship between cell size and aortic valve morphology, but no
significant difference in cell size was found between TAV and BAV ECFCs (p = 0.9387) (Figure 2B).
To determine if the variation in cell size is caused by changes in cell growth, cell proliferation rate
was measured and depicted as the difference in cell number 24 and 72 h after seeding. As can
be appreciated in Figure 2C, no difference in proliferation rate between TAV and BAV ECFCs was
observed (p = 0.8407). In addition, there was no correlation between cell proliferation and cell size
when comparing average proliferation rate and cell size per ECFC line (p = 0.321, data not shown).
Furthermore, since during epithelial-to-mesenchymal transition (EMT) an increase in size of epithelial
cells in transition is observed [24], we next analyzed if there was a correlation between cell size and
EndoMT gene transcription, but no significant differences were observed (data not shown).
2.4. BAV ECFCs Migrate Faster Compared to TAV ECFCs
Previous studies have shown that poor cell migration of EPCs correlated with worse valvular
function in BAV [13]. Therefore, we next determined migration of ECFCs using two different assays,
transwell and scratch assay. In order to assess the intrinsic migratory potential of the ECFCs, we first
performed a transwell assay using serum as a migratory stimulus, and visualized the migrated
cells using crystal violet (Figure 3A). There was a remarkable significant increase in migration of
BAV ECFCs compared to TAV ECFCs (TAV: M = 87.2 SEM = 13.6, BAV: M = 193.9 SEM = 22.0,
p = 0.0029) (Figure 3B). Next we performed a scratch (wound healing) assay. To determine the wound
healing response, we calculated the difference in surface area between 2 timepoints. The scratch assay
confirmed the difference observed in the transwells. There was a significant increase in wound closure
by BAV ECFCs compared to TAV ECFCs (TAV: M = 6.73 SEM = 0.56, BAV: M = 10.03 SEM = 0.82,
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p = 0.020) (Figure 3C,D). Sempahorin3C (sema3C), a secreted guidance protein, regulates endothelial
migration [25]. We therefore quantified Sema3c expression by qRT-PCR in TAV and BAV ECFCs, and
observed a trend towards an increase in Sema3C expression in BAV ECFCs compared to TAV ECFCs
(Figure 3E). Taken together, we show that migration of cells is reduced in BAV ECFCs.
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Figure 2. ECFC proliferation rate and cell size in TAV and BAV. (A) Representative images of variation
in cell size in TAV and BAV ECFCs. The scale bar is 200 µm. (B) Graph showing TAV and BAV ECFC
cell size. (C) Graph indicating TAV and BAV ECFC proliferation.
2.5. Calcifi ation Is Decreased in BAV ECFCs Compared to TAV ECF s
Since val ular cal ification is a serious complication i BAV patients, we studied the ability of the
BAV and TAV ECFCs to calcify. After culturing ECFCs in osteogenic medium we stained the wells
with Alizarin Red (Figure 4A). Interestingly, calcium deposits could already be detected in some of the
samples after being cultured for 18 days in growth medium. These deposits were more present in the
BAV than the TAV ECFCs; however, the difference was not significant (TAV: M = 0.35% SEM = 0.24,
BAV: M = 0.97% SEM = 0.41, p = 0.31) (Figure 4A,B, Figure A2a). Culturing the cells osteogenic medium
increased the amount of Alizarin Red staining in the TAV and BAV ECFCs when compared to growth
medium. Although both showed an increase in calcium deposition, this increase is less in BAV ECFCs
when compared to TAV ECFCs when cultured in osteogenic medium (Figure 4A,B, Figure A2a).
Previously it has been shown that inorganic phosphate transporter 1 and 2 (PiT1 and PiT2)
are expressed in progenitor cells during differentiation towards osteoblasts [26]. Furthermore, an
increased expression of PiT1 is related to increased mineralization and shown to be involved in SMC
transdifferentiation into osteoblast-like cells [27,28]. Therefore, we determined whether PiT1 and PiT2
may play a role in ECFC calcification and found a trend towards increased expression of both PiT1 and
PiT2 in BAV ECFCs compared to TAV ECFCs under normal culture conditions (Figure 4C, Figure A2b).
Inflammatory stimulation using tumor necrosis factor (TNF)-α has been reported to sensitize
ECFCs for calcification [29]. Therefore, we stimulated ECFCs with TNFα for 48 h and de ermined the
expression levels of PiT1 and PiT2. Interestingly, PiT2 expression upon TNFα significantly incr ased in
TAV ECFCs (p = 0.0157, 24.8%, SEM = 0.05) but not in BAV ECFCs (p = 0.788, −4.5%, SEM = 0.166)
(Figure 4D). In addition, the expression of PiT1 showed a similar trend (Figure A2c). In summary,
ECFCs from BAV patients exhibit a reduced capacity to calcify when compared to TAV derived
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ECFCs and TNF-α stimulation specifically induced the expression of PiT2 in TAV ECFCs, but not in
BAV ECFCs.
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3. Discussion
In this study, we isolated ECFCs from BAV patients and TAV controls to study EC function,
and observed a striking decrease in efficiency of successful ECFC isolation in BAV patients with a
dilated aorta. In the ECFCs that were successfully isolated, proliferation rate and cell size were similar,
but there was a decrease in migratory behavior of ECFCs from BAV patients when compared to TAV
patients. While no differences were detected in their response to TGFβ induced EndoMT, we did
observe a reduced calcification response in BAV ECFCs compared to TAV ECFCs.
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Normal endothelial function is pivotal for a healthy cardiovascular function. In the past years,
research to understand bicuspid aortic valve disease has suggested that endothelial dysfunction
might play a role [7,9,30]. In vitro characterization of ECs isolated from aneurysmal aortic tissue
show a decreased proliferation rate in BAV aortic ECs compared to TAV control and TAV aneurysmal
ECs [31]. Unfortunately, primary ECs isolated from aortic tissue are heterogeneous, have very limited
proliferative capacity and can only be obtained from end stage disease surgical material, hampering
progress in our understanding of the impact of the endothelium in BAV. Therefore, we took the approach
to generate ECFC cell lines from BAV patients to study EC function. ECFCs not only provide an in vitro
cell model for patient specific endothelial functioning, but in vivo they contribute to endothelial wound
healing [14–16]. Therefore, altered function of ECFCs might contribute to endothelial dysfunction when
e.g., repairing the endothelial layer damaged due to years of altered wall shear stress [32]. Although
the behavior of ECFCs might not fully recapitulate the ECs present in the aortic wall, these cells cannot
be obtained from healthy matched controls. ECFCs are an EC source that most closely resemble mature
ECs obtained using a minimal invasive isolation protocol [11,14]. Peripheral ECs can also be isolated to
study patient specific EC functioning, but they have been reported to have clear different characteristics
from aortic ECs, and would cause a higher isolation burden. Therefore, we decided to use ECFCs to
study patient specific EC function [33].
The isolation efficiency of ECFCs from BAV patients with a non-dilated aorta was similar to TAV
control. Interestingly, we were unable to isolate ECFCs from BAV patients with an aortic dilation.
This observation might suggest a possible biomarker role of ECFCs in BAV aortic dilation. A recent
study analyzing EPCs reported a reduced number of EPCs in BAV patients with a dysfunctional aortic
valve when compared to a normal functioning BAV [13]. A decrease in circulating progenitor cells in
BAV patients with additional cardiovascular pathologies could explain the lack of successful ECFC
isolations from dBAV patients. Incongruently, we were able to successfully isolate ECFCs from patients
with valvular dysfunction. Moreover, we did not observe a difference between the number of colonies
that appeared in isolations from BAV patients with or without aortic dilation compared to TAV ECFCs.
We did observe a difference in the proliferative capacity of the different colonies. All colonies isolated
from dBAV patients stopped proliferating soon after appearing and gained a senescent/mesenchymal
morphology. Recent studies have shown that there was an increase in EndoMT gene expression profile
associated with a BAV [7,9,22,23]. Increased EndoMT could be the cause of an increased amount of BAV
colonies to gain a mesenchymal phenotype. Moreover, as epithelial cell size has been correlated to EMT,
the different cell sizes observed in the ECFC culture could be related to an EndoMT phenotype [24].
However, in the BAV ECFCs we did not observe a difference in upregulation of expression of EndoMT
related genes upon TGFβ stimulation between TAV and BAV ECFC cell lines. Moreover, we did not
observe a correlation between cell size and the expression of different EndoMT related target genes.
Although increased age has been reported to impair ECFC isolation [34], but we did not observe
a significant age difference when comparing successful and non-successful isolations in this study.
There was, however, a significant increase in age of patients with a dilated aorta compared to BAV
patients without a dilated aorta.
To study EC behavior, migration of the ECFCs was investigated. Our data shows that migration is
increased in BAV ECFCs when compared to TAV ECFCs. Moreover, BAV ECFCs show an increase in
Sema3C expression, a secreted protein that regulates EC function and enhances migration. Reduced EC
migration in vitro has been found in many different diseases, e.g., in ECFCs derived from patients with
diabetes or preeclampsia [35,36], and related to the functionality of the patient specific ECs. In contrast
to diabetes and preeclampsia, we observed an increase in migration of ECFCs derived from BAV
patients, leaving us to speculate how this affects the function in vivo. Migratory behavior has been
studied using aortic SMCs from BAV patients with an aortic aneurysm. When comparing them to
TAV non-aneurysmal aortic SMCs, these BAV SMCs show a decreased migration rate [31]. Either no
difference, or reduced migration has been observed in SMC migration from BAV aneurysmal aorta
when compared to TAV aneurysmal aorta. Since no SMCs were isolated from BAV with a non-dilated
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aorta it is difficult to draw any conclusion if SMC migration in BAV patients is already altered prior to
vessel dilation. Finally, a decrease in migration of BAV EPCs was related to increased dysfunction in
aortic valves [13], but unfortunately our study is not sufficiently powered to be able to relate patient
characteristics to aortic valve dysfunction.
Because valvular calcification is a common problem in a subpopulation of patients with a BAV,
we studied calcification of the ECFCs. Interestingly, BAV ECFCs cultured in a well for 18 days on
growth medium show more calcium deposits compared to TAV. Moreover, expression of PiT1, a gene
shown to be involved in calcification, shows a modest increase in BAV ECFCs [26–28]. Since patients
with a BAV have a high chance to develop calcific aortic valve disease (CAVD), we expected BAV
ECFCs to calcify more than TAV ECFCs. However, upon osteogenic stimulation, BAV ECFCs showed a
much smaller increase in calcium deposition than TAV ECFCs did. This unexpected result might be
explained by differences between in vitro and in vivo cell function, and/or the calcifying stimulation
in vivo in BAV is different from our experimental set-up. It does, however, confirm that the calcification
response in BAV ECFCs is altered compared to TAV ECFCs. Inflammatory stimulation using TNFα
has been shown to sensitize ECFCs for calcification [29]. Moreover, a recent study on a large CAVD
cohort showed that inflammatory markers were increased in CAVD BAV patients compared to CAVD
TAV patients [37]. Therefore, we stimulated the ECFCs with TNFα, which caused significant increase
in mRNA expression of PiT2 in TAV ECFCs but not in BAV ECFCs. This lack of increase in PiT2 could
explain the reduced response of BAV ECFCs to osteogenic medium.
In this study we have for the first time characterized ECFCs from BAV patients. Our data suggests
that EC dysfunction is present in these patients, and future research should focus on the role of
endothelial dysfunction in the pathogenesis of BAV and the related aortic valve calcification and aortic
dilation, taking into account the role of BAV related genes that are known to affect cell migration,
proliferation, EndoMT and calcification such as SMAD6, NOTCH1 or TGFβR1 [1,2] [38–41]. Altogether,
we expect that this study will stimulate the use of ECFCs as a surrogate model to determine endothelial
function in BAV.
4. Materials and Methods
Ethical approval for this study was obtained from the Medical Ethical Committee from the
Leiden University Medical Center (METC LUMC), Leiden, The Netherlands (P15.377, approved on
02-June-2016). The included patients were 18 years of age or older, had a bicuspid aortic valve and were
invited to participate during routine visit to the outpatient clinic. Patients were excluded if they had
undergone aortic valve surgery or intervention. Control participants were age and gender matched to
the average of the patient population and a TAV was confirmed. The ascending aortic diameter was
measured with echocardiography using the leading edge-to-leading edge technique [42]. An ascending
thoracic aortic diameter equal to or larger than 40 mm was considered dilated. After obtaining written
informed consent, peripheral blood (60 mL) was drawn from BAV patients and TAV control participants.
To isolate the mononuclear cell fraction, the blood was diluted 1:1 with PBS and centrifuged using a
ficoll gradient. In detail, the sample was divided in fractions of 25 mL which were gently pipetted
in a 50 mL tube on top of 12.5 mL Ficoll Paque Plus (GE Healthcare, 17-1440-03, Chicago, Il, USA).
The tubes were centrifuged at 750 G for 30 min without brake. The plasma layer was aspirated, and
the buffy coat of the mononuclear cell fraction was transferred to a new 50 mL tube. The cells were
washed 3× with PBS supplemented with PenStrep (100 U/mL, Thermo Fischer Scientific, Waltham, MA,
USA) by adding 25 mL PBS to the tube, centrifuging 5 min at 230 G and aspirating the supernatant.
The pellet was resuspended in 12.5 mL growth medium (EGM-2 (Lonza, CC-3162, Basel Switzerland)
supplemented with 8% extra fetal bovine serum (FBS) and PenStrep (100 U/mL, Gibco). 48-Well plates
were coated with 50 µg/mL purified bovine collagen (Advanced Biomatrix, #5005, Carlsbad, CA, USA)
in MQ, 250 µL per well and were incubated 2 h at 37 ◦C and washed 3× using PBS before plating the
resuspended cells. The medium was replaced for the first time after 3 days using growth medium,
after which the medium was replaced 2 times per week. Colonies that appeared 2 to 5 weeks after
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isolation were passaged when covering approximately 25% of the well. Cells were dissociated by
incubating the ECFCs for 1 min with EDTA (0.5 mM, Sigma, Saint Louis, MO, USA) followed by
incubation with Trypsin 0.25%/EDTA (1:1 Serva, Heidelberg, Germany) for approximately 5 min until
cells were dissociated from the well. This dissociation was confirmed using a microscope, after which
they were resuspended and reseeded 1:2 onto collagen coated wells. The ECFCs were checked for
expression of PECAM1 (qRT-PCR and Western blot) and VE-Cadherin (qRT-PCR) expression and
absence of the lymphocyte marker CD45 was confirmed.
4.1. Protein Isolation and Western Blot
To isolate protein, ECFCs were grown to confluence, washed with PBS and lysed in Giordano
buffer (50 nM Tris-HCl (pH7.4), 250 mM NaCl, 0.1% Triton X-100 and 5 mM EDTA) with 15% glycerol
and protease inhibitors. Protein concentration was determined using Bradford Reagent (Bio-Rad,
500-0006, Hercules, CA, USA). Equal amounts of protein were loaded and separated by SDS-PAGE and
transferred to Immobilon-P PVDF membranes (Merck, IPVH00010, Darmstadt, Germany). Membranes
were blocked in Tris-buffered saline, 0.2% Tween-20 (TBST) containing 10% dry milk and incubated
overnight with Pecam1 antibody (Santa Cruz Biotechnology, sc-1506-r, clone M-20, Dallas, TX, USA)
diluted 1:1000 in 5% BSA in TBST. Membranes were washed 3 times with TBST and incubated with a
horseradish peroxidase-conjugated goat-anti-rabbit antibody (Thermo Fischer Scientific, 31458) diluted
1:10,000 in 10% dry milk in TBST. Membranes were washed with TBST again, after which protein
expression was detected using enhanced chemiluminescence (WesternBright Quantum, Advansta,
San Jose, CA, USA) and visualized on x-ray film (Fuji film, Minato, Tokia, Japan).
4.2. mRNA Isolation and Quantitative RT-PCR
RNA was isolated using the ReliaPrep RNA cell miniprep kit (Promega, Z6012, Madison, WI.
USA) according to the manufacturer’s protocol. RevertAid First Strand cDNA Synthesis (ThermoFisher
Scientific, K1622) was used to generate cDNA according to the manufacturer’s protocol, after which
qRT-PCR was performed using GoTaq qPCR Master Mix (Promega, A6001). GAPDH and ARP were
used as housekeeping genes. Primer sequences used are detailed in the Supplementary Materials.
4.3. Cell Size
To measure cell size, pictures were acquired from confluent areas. In these pictures, the number
of cells was determined in an area of 2 mm2 from which an average cell surface area was calculated.
Then the average cell surface area was calculated (2 mm2/number of cells).
4.4. Proliferation
Cell proliferation was determined by calculating the increase in cell number in 48 h. To this end,
15,000 cells were seeded per cm2 in growth medium which did not reach confluency before the end
of the experiment. To quantify proliferation, cells were dissociated to single cells 24 and 72 h after
seeding and automatically counted 3 times using a TC20 automated cell counter (Bio-Rad). The ratio
between the number of cells of day 3 and day 1 was used as an indication for proliferation rate.
4.5. MTT and PrestoBlue Assays
MTT and PrestoBlue assays were used to determine proliferation rate. For both assays
3000 cells/well were seeded in 96-well plates in a final volume of 100 µL/well. For the MTT
assay, the growth medium was replaced by growth medium supplemented with 0.5 mg/mL
3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT, Sigma M5655) for 3 hours at 37 ◦C,
16 (t1) and 40 h (t2) after seeding. The absorbance was measured at 595 nm, as described previously [43].
For the PrestoBlue assay, the growth medium was replaced with growth medium supplemented with 4%
PrestoBlue Cell Viability Reagent (ThermoFisher, A13261). After 3 h of incubation at 37 ◦C, fluorescence
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was measured at 590 nm as a read out for mitochondrial respiration on a victor3V multilabel reader
(Perkin Elmer, Waltham, MA, USA). Three technical replicates were included in each experiment and
assays were repeated at least twice.
4.6. EndoMT Assay
To induce EndoMT, growth medium supplemented with 5 ng/mL TGFβ3 was added to a 6-wells
well of ECFCs with a confluency of 60%. After 48 h, the cells were washed with PBS and RNA was
isolated as described above.
4.7. Transwell Migration
To measure migration towards a stimulus, a transwell migration assay was performed. A transwell
insert with 5µm pores (Corning, CLS3421-48EA, Corning, NY, USA) was coated using 50 µg/mL
bovine-collagen. Next, 10,000 ECFCs in 100 µL EGM2 (2%FBS) were seeded into the transwell insert.
The bottom well contained 600 µL growth medium (10% FBS). After 24 h, the inserts were washed
with PBS and fixated for 10 min with 4% paraformaldehyde (PFA) before staining the membrane with
4% Crystal violet (Sigma, C0775) in methanol. The ECFCs that did not migrate through the membrane
were removed before taking pictures. Migrated ECFCs were counted from the pictures taken (5 images
per transwell).
4.8. Scratch Migration
A scratch assay was performed as an in vitro model for wound healing. The scratch assay was
performed in a 24 well with a confluent layer of cells. Cells were scraped using a 200 µL tip after which
they were automatically imaged for 24 h. To calculate the migration rate, the open area was measured
at 8 and 12 h after making the scratch. The difference in area between the timepoints was determined
to calculate the migration speed.
4.9. Calcification Assay
To study calcification, ECFCs were seeded in triplo in 48-wells plates. When reaching confluency,
the ECFCs were incubated with osteogenic medium (growth medium supplemented with 2.7 mM
CaCl2 and 2.5 mM NaH2PO4) which was replaced twice-weekly. After 18 days, the ECFCs were fixated
using 4% PFA for 10 min, washed with MQ and incubated with 2% Alizarin Red (Sigma, TMS-008-C,
pH 4.2) in MQ for 3 min. The plates were washed again 2× with MQ before imaging. Surface area of
AR in the images was automatically measured using Fiji [44]. Finally, the alizarin red was dissolved
by replacing the MQ with 150 µL cetylperidiumchloride for 3 h at 37 ◦C, after which the absorbance
was measured in duplo at 595 nm. To study the effect of inflammation on calcification, ECFCs were
stimulated with 10 ng/mL TNFα (Peprotech, 300-01A, Rocky Hill, NJ, USA) for 48 h before isolating
RNA, as described above, and studying gene expression by qRT-PCR.
4.10. Statistics
All results were obtained in at least 4 independent experiments. The isolation and initial culture,
as well as the first round of experiments were performed while blinded. Statistical assays were
performed using Graph Pad Prism (version 7). Correlations were tested using Pearson correlation.
All other statistical tests were performed using Students t-test, except from the number of colonies per
patient, which was analyzed using Fischer’s exact test and one-way ANOVA for the % of successful
colony growth. qRT-PCR results from the experiments with TNFα and TGFβ stimulation are related
to the non-stimulated control per cell line. p-values < 0.05 (*), 0.01 (**), 0.001(****) were considered
significantly different.
Supplementary Materials: Supplementary materials can be found at http://www.mdpi.com/1422-0067/20/13/
3251/s1.
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Abbreviations
BAV Bicuspid aortic valve
CAVD Calcific aortic valve disease
ECFC Endothelial Colony Forming Cells
EC Endothelial cell
EPC Endothelial Progenitor Cells
EndoMT Endothelial-to-Mesenchymal transition
FBS Fetal Bovine Serum
TAV Tricuspid aortic valve
TGFβ Transforming growth factor β
TNFα Tumor necrosis factor α
Appendix A
Table A1. BAV patient characteristics with/without aortic dilation.
Non-Dilated Aorta (17) Dilated Aorta (17)
Male Sex, n (%) 7 (41.2) 11 (64.7)
Age, year (stdev) 28.9 (7.8) 47.9 (15.7) #
Height, cm (stdev) 173.9 (11.8) 178.4 (9.9)
Weight, kg (stdev) 69.5 (12.5) 84.2 (12.9) **
Valve Types, n (%)
Type 0 4 (23.5) 1 (5.9)
Type 1 L-R 8 (47.1) 9 (52.9)
Type 1 R-N 1 (5.9) 3 (17.6)
Type 2 L-R, R-N 1 (5.9) 1 (5.9)
Unknown 3 (17.6) 3 (17.6)
Aortic Size, mm (stdev) 30.2 (3.0) 43.1 (5.5)
Stenosis, n (%)
Severe 2 (11.8) 1 (5.9)
Moderate 3 (17.6) 4 (23.5)
Mild 2 (11.8) 3 (17.6)
None 10 (58.8) 9 (52.9)
Insufficiency, n (%)
Moderate 2 (11.8) 7 (41.2)
Mild 3 (17.6) 4 (23.5)
Trace 4 (23.5) 2 (11.8)
None 8 (47.1) 4 (23.5)
** p < 0.01, # = p<0.0001.
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Figure A1. EndoMT related gene expression in TAV and BAV ECFCs upon TGFβ stimulation. Graphs 
showing the relative increase in expression upon TGFβ stimulation compared to not stimulated cells 
of (A) TAGLN, (B) SNAIL and (C) FN1. ** p < 0.01. 
 
Figure A2. Calcification results of TAV and BAV ECFCs. (A) Graph of TAV and BAV calcification 
measured using absorbance after dissolving alizarin red. (B) Graph indicating Pi2 gene expression in 
BAV and TAV ECFCs under normal culture conditions. (C) Graph showing PiT1 gene expression 
levels upon ECFC stimulation with TNFα. * p < 0.05. 
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